Sporadic Creutzfeldt-Jakob disease
ORPHA:204DiseaseNot applicableAdult, Elderly
Фенотипы (HPO)37
Очень частый (80–99%)5
HP:0000726Dementia
HP:0002529Neuronal loss in central nervous system
HP:0006790Cerebral cortex with spongiform changes
HP:0012672Akinetic mutism
HP:0030890Hyperintensity of cerebral white matter on MRI
Частый (30–79%)16
HP:0000708Atypical behavior
HP:0001251Ataxia
HP:0001289Confusion
HP:0001336Myoclonus
HP:0002059Cerebral atrophy
HP:0002100Recurrent aspiration pneumonia
HP:0002171Gliosis
HP:0002354Memory impairment
HP:0002367Visual hallucinations
HP:0002446Astrocytosis
HP:0002521Hypsarrhythmia
HP:0002719Recurrent infections
HP:0002922Increased CSF protein concentration
HP:0004887Respiratory failure requiring assisted ventilation
HP:0100543Cognitive impairment
HP:0100806Sepsis
Периодический (5–29%)16
HP:0002315Headache
HP:0002321Vertigo
HP:0002360Sleep abnormality
HP:0002371Loss of speech
HP:0002493Upper motor neuron dysfunction
HP:0003487Babinski sign
HP:0006801Hyperactive deep tendon reflexes
HP:0007256Abnormal pyramidal sign
HP:0012378Fatigue
HP:0000505Visual impairment
HP:0000712Emotional lability
HP:0000716Depression
HP:0000737Irritability
HP:0000741Apathy
HP:0001257Spasticity
HP:0002071Abnormality of extrapyramidal motor function
Эпидемиология50
| Тип оценки | Класс распространённости | Среднее (на 100к) | Регион | Квалификация |
|---|---|---|---|---|
| Annual incidence | 1-9 / 1 000 000 | 0.125 | Australia | Value and class |
| Point prevalence | <1 / 1 000 000 | 0.0937 | Australia | Value and class |
| Annual incidence | 1-9 / 1 000 000 | 0.152 | Austria | Value and class |
| Point prevalence | 1-9 / 1 000 000 | 0.114 | Austria | Value and class |
| Annual incidence | 1-9 / 1 000 000 | 0.117 | Belgium | Value and class |
| Point prevalence | <1 / 1 000 000 | 0.087 | Belgium | Value and class |
| Annual incidence | 1-9 / 1 000 000 | 0.105 | Canada | Value and class |
| Point prevalence | <1 / 1 000 000 | 0.078 | Canada | Value and class |
| Annual incidence | 1-9 / 1 000 000 | 0.12 | Czech Republic | Value and class |
| Point prevalence | <1 / 1 000 000 | 0.09 | Czech Republic | Value and class |
| Annual incidence | 1-9 / 1 000 000 | 0.104 | Cyprus | Value and class |
| Point prevalence | <1 / 1 000 000 | 0.078 | Cyprus | Value and class |
| Annual incidence | 1-9 / 1 000 000 | 0.147 | Denmark | Value and class |
| Point prevalence | 1-9 / 1 000 000 | 0.11 | Denmark | Value and class |
| Annual incidence | <1 / 1 000 000 | 0.032 | Estonia | Value and class |
| Point prevalence | <1 / 1 000 000 | 0.024 | Estonia | Value and class |
| Annual incidence | 1-9 / 1 000 000 | 0.141 | Finland | Value and class |
| Point prevalence | 1-9 / 1 000 000 | 0.105 | Finland | Value and class |
| Annual incidence | 1-9 / 1 000 000 | 0.16 | France | Value and class |
| Point prevalence | 1-9 / 1 000 000 | 0.12 | France | Value and class |
| Annual incidence | 1-9 / 1 000 000 | 0.133 | Germany | Value and class |
| Point prevalence | <1 / 1 000 000 | 0.099 | Germany | Value and class |
| Annual incidence | <1 / 1 000 000 | 0.062 | Greece | Value and class |
| Point prevalence | <1 / 1 000 000 | 0.0465 | Greece | Value and class |
| Annual incidence | 1-9 / 1 000 000 | 0.0107 | Hungary | Value and class |
| Point prevalence | <1 / 1 000 000 | 0.08 | Hungary | Value and class |
| Annual incidence | 1-9 / 1 000 000 | 0.142 | Italy | Value and class |
| Point prevalence | 1-9 / 1 000 000 | 0.1065 | Italy | Value and class |
| Annual incidence | 1-9 / 1 000 000 | 0.123 | Netherlands | Value and class |
| Point prevalence | <1 / 1 000 000 | 0.092 | Netherlands | Value and class |
| Annual incidence | 1-9 / 1 000 000 | 0.102 | Norway | Value and class |
| Point prevalence | <1 / 1 000 000 | 0.0765 | Norway | Value and class |
| Annual incidence | <1 / 1 000 000 | 0.0086 | Slovakia | Value and class |
| Point prevalence | <1 / 1 000 000 | 0.0645 | Slovakia | Value and class |
| Annual incidence | 1-9 / 1 000 000 | 0.146 | Slovenia | Value and class |
| Point prevalence | 1-9 / 1 000 000 | 0.1095 | Slovenia | Value and class |
| Annual incidence | 1-9 / 1 000 000 | 0.128 | Spain | Value and class |
| Point prevalence | <1 / 1 000 000 | 0.096 | Spain | Value and class |
| Annual incidence | 1-9 / 1 000 000 | 0.142 | Sweden | Value and class |
| Point prevalence | 1-9 / 1 000 000 | 0.1065 | Sweden | Value and class |
| Annual incidence | 1-9 / 1 000 000 | 0.173 | Switzerland | Value and class |
| Point prevalence | 1-9 / 1 000 000 | 0.129 | Switzerland | Value and class |
| Annual incidence | <1 / 1 000 000 | 0.055 | Taiwan, Province of China | Value and class |
| Point prevalence | <1 / 1 000 000 | 0.041 | Taiwan, Province of China | Value and class |
| Annual incidence | 1-9 / 1 000 000 | 0.124 | United Kingdom | Value and class |
| Point prevalence | <1 / 1 000 000 | 0.093 | United Kingdom | Value and class |
| Annual incidence | 1-9 / 1 000 000 | 0.122 | United States | Value and class |
| Point prevalence | <1 / 1 000 000 | 0.0915 | United States | Value and class |
| Point prevalence | <1 / 1 000 000 | 0.088 | Worldwide | Value and class |
| Annual incidence | 1-9 / 1 000 000 | 0.118 | Worldwide | Value and class |
Лекарства и терапия
Источник: Open Targets Platform (в реальном времени)
Клинические исследования
Источник: ClinicalTrials.gov (в реальном времени)